Clinical Trial Update: Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating vaccination with tumor-derived immunoglobulin idiotype for follicular lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Idiotype vaccine (tumor-derived immunoglobulin idiotype) (tumor-derived immunoglobulin idiotype vaccine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B Cell Lymphoma, Follicular Lymphoma | Phase 1 | Status: COMPLETED